Measuring Tablet Hardness: A Primer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Measuring Tablet Hardness: A Primer
Crushing, fracturing, and bending tests quantify hardness.


Equipment and Processing Report

Solid tablets are perhaps the most commonly used dosage form for pharmaceuticals. Tablet hardness serves both as a criterion to guide product development and as a quality-control specification. Tablets should not be too hard or too soft. An extremely hard tablet could indicate excessive bonding potential between active ingredients and excipients, which can prevent proper dissolution of the tablet needed for an accurate dosage. By the same token, a softer tablet could be due to weak bonding and may lead to premature disintegration when ingested by the patient. A soft tablet could also chip or break during processing stages in manufacturing, such as coating and packaging.

Figure 1. Crush test on tablet (CT3 Analyzer, Brookfield Engineering)

Knowing the mechanical properties of a solid-dose tablet can provide valuable information for optimizing material constituents and the manufacturing process. The types of binders used, the nature of the active ingredient(s), and the composition of the ingredient(s) in the tablet will affect the hardness of the tablet; the tablet-press speed, granulation flow, and air in the powder can also potentially affect tablet hardness (1). These factors must be controlled during production and verified after manufacture. As the production-to-market timeline of pharmaceutical products becomes tighter, it is essential to efficiently and effectively quantify the critical properties that will affect product development and performance. Methods for measuring the mechanical strength of a tablet include crushing, fracturing, and bending tests (2).

The crush test is usually performed on a round tablet standing on its rim, or, for a capsule-like tablet, parallel to the longest axis. This test is sometimes known as a diametrical compression test. The test sample is placed on a base table and compressed against a flat surface cylindrical probe, as shown in Figure 1 (CT3 Analyzer, Brookfield Engineering). The cylindrical probe surface, which is larger than the test sample, is moved down to crush the tablet at a constant speed, and the force applied to crush the tablet is measured. The load-force values obtained will depend on the construction and size of the tablet. A plot of force load (g) vs. time (s) as the test progresses is obtained (TexturePro CT software program, Brookfield Engineering). The highest point on the graph, peak load, is the load required by the analyzer to break the tablet. This point also indicates the tablet’s maximum strength before breaking.

The fracture test is accomplished by driving a smaller hemispherical ball probe into the flat surface of a solid tablet (see Figure 2). A suitable probe deformation distance must be chosen to avoid base effect, which is the external influence of the substrate surface on which the tablet is placed. Base effect is caused by compression of a thin sample against the test bed of the analyzer instrument, which inadvertently renders incorrect results. A deformation distance of not more than 60% of the sample height is usually enough for the ball probe to fracture the tablet without causing base effect. The maximum strength of a tablet before breaking is the peak load on the graph plot. The recorded force applied to fracture the tablet is useful for determining mechanical properties, such as Young’s modulus and tensile strength. Young’s modulus, which is the ratio of stress over strain deformation (E = σ/ε), describes the stiffness and toughness of a material.

Figure 2. Fracture test on tablet (CT3 Analyzer, Brookfield Engineering)

Another common fracture test on tablets is the snap or bending test. This test is common for an oval tablet shaped like a capsule (i.e., caplet) as well as on a fairly large round tablet. The test is performed with a three-point bend fixture; the tablet is supported at either end and deformed in its center with a knife-like probe, causing it to fracture and break at its weakest point. To ensure comparability of results, the tablet’s orientation in the fixture must be standardized, preferably in a manner that is most readily and easily reproduced by operators (e.g., align the score line of the tablet with the probe blade). The peak load indicates the tablet hardness; harder tablets will give a higher peak load. The distance to peak load is an indication of the elasticity of the test sample. Brittle samples (such as solid-dose tablets) will have a shorter distance or time at failure hardness compared to elastic samples.

These tablet hardness tests provide a meaningful picture as to the amount of force required to fracture the solid-dose tablet. This knowledge will be useful in gauging the tablet’s resistance to damage that might occur during production handling, packaging, and storage. Based on this testing, guidelines for acceptable hardness values can be established. The test is also useful for quantifying the internal bonding strength of powder, which will help to achieve compatibility of formulation with performance specifications. Tests can also be used to enhance the production evaluation of tablet consistency between different batches, shifts, and facilities.

Images are courtesy of the author.

References

  1. P. N. Davis and J.M. Newton, “Mechanical strength” in Pharmaceutical Powder Compaction Technology, G. Alderborn and C. Nystrom, Eds. (Marcel Dekker, New York, 1996), pp. 165–191.
  2. J.M. Newton, G. Alderborn, and C. Nystrom, Pow. Technol. 72 (1) 97–99 (1992).

Eric Chiang is product manager for texture analyzers at Brookfield Engineering Laboratories, Middleboro, MA; tel: 1.800.628.8139; email: e_chiang@brookfieldengineering.com; www.brookfieldengineering.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Equipment and Processing Report,
Click here